Company intelligence / Profile preview

DuChemBio

Seoul, South Korea

Ownership: Private
Employees: ~115
Development stage: Other

Overview

DuChemBio has a wide portfolio of commercial and locally-developed radiopharmaceuticals for diagnostic imaging (PET/CT and PET/MRI), including products for Parkinson's disease, Alzheimer's disease, brain tumors, and neuroendocrine tumors. The company also manufactures/distributes cutting-edge investigational agents in partnership with global biotech companies and supports international clinical trials.

Therapeutic areas: OncologyNeurology
Modalities: RadiopharmaceuticalSmall moleculeImaging agent
Industry: Medical Imaging

Partnerships

ImaginAb (CD8 ImmunoPET agent manufacturing/distribution)Telix Pharmaceuticals (commercialization and partnership agreement)major Korean hospitals and research institutes

Beyond the preview

Go deeper on DuChemBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DuChemBio.

Explore the full profile